Abdul Mannan: Perioperative Bridging of Warfarin Patients Is a Risk-Based Decision
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Your patient on warfarin needs an endoscopy.
One colleague says bridge.
Another says don’t.
Here is how to settle it.
Most people default to ‘yes, always’ or ask a colleague who guesses. Here is the actual answer.
Bridge with therapeutic-dose LMWH when:
- VTE within the last 3 months
- VTE on therapeutic anticoagulation (target INR 3.5 — very high risk, includes high-risk APS)
- AF with stroke or TIA within the last 3 months
- AF with prior stroke/TIA plus 3 or more of: CCF, hypertension, age over 75, diabetes
- Mechanical heart valve — any type, except one caveat below
Do not bridge when:
- VTE more than 3 months ago — prophylactic-dose LMWH post-op is sufficient (Grade 2C)
- AF with CHADS₂ of 4 or less, no recent stroke or TIA (Grade 1A)
- Bileaflet aortic valve with no other risk factors (Grade 2C)
- DOAC patient — full stop. Simple interruption only. The PAUSE trial settled this
Practical warfarin steps:
Stop 5 days before the procedure (Grade 1C)
Check INR the day before.
Give vitamin K if INR is 1.5 or above
If Bridging required Bridge with Therapuetic LMWH
Restart warfarin at normal maintenance dose the same evening as surgery
Post-op full-dose bridging: Wait at least 48 hours if high bleeding risk (Grade 1C)
The pause trial showed that simple DOAC interruption without bridging was associated with low rates of both bleeding and thromboembolism across AF, VTE, and mechanical valve populations.
Warfarin bridging rules above are consistent with Veitch AM et al, (BSG/ESGE guideline update — PMID not verified this session).
What is the trickiest bridging decision you face in practice?”
Find more posts featuring Abdul Mannan on Hemostasis Today.
-
Oct 7, 2026, 10:42Nasir K.: The Global Healthcare Community Comes Together for IPAW 2026
-
Oct 7, 2026, 09:20Maurizio Bertaina: Optimizing Anticoagulation in Temporary Mechanical Circulatory Support
-
Oct 7, 2026, 08:55Ifeanyichukwu Ifechidere: Cancer, Clotting and Bleeding – The Critical Role of Haemostasis in Oncology
-
Oct 7, 2026, 08:39Pediatric Hematology – Careers in Thrombosis and Blood Disorders – ASH Education
-
Oct 7, 2026, 07:57Edward Lee Carter: When Should Apixaban Become the Default for Acute VTE?
-
Oct 7, 2026, 07:40Annette Bowyer: Exploring New Developments in Thrombin Generation
-
Oct 7, 2026, 07:06Omid Seidizadeh: When Acquired von Willebrand Syndrome Takes Different Paths
-
Oct 7, 2026, 06:49Neeraj Songara: Can a Negative Antibody Screen Be Misleading?
-
Oct 7, 2026, 04:09James P. Crowley: Could the Microbiome Protect Us From Severe EBV Infection?